(M12) M1 Kliniken - Ratings and Ratios

M1 Kliniken AG is a leading provider of aesthetic medicine and plastic surgery services across 10 countries, including Germany, Austria, the Netherlands, Switzerland, the United Kingdom, Croatia, Hungary, Bulgaria, Romania, and Australia. The company operates through two distinct segments: Beauty and Trade. The Beauty segment specializes in surgical and non-surgical aesthetic treatments, such as breast augmentation, eyelid lifts, liposuction, and injections with hyaluronic acid and botulinum toxin. It also manages private clinics and medical specialist centers under the Schlossklinik and M1 Med Beauty brands, offering comprehensive aesthetic and plastic medicine services. The Trade segment focuses on the distribution of pharmaceuticals and medical products across various therapeutic areas, including oncology, HIV/AIDS, neurology, rheumatology, chronic diseases, and aesthetic medicine. Established in 2007 and headquartered in Berlin, Germany, M1 Kliniken AG is a subsidiary of MPH Health Care AG and has built a strong presence in the European and Australian markets for aesthetic medical services.

From a financial perspective, M1 Kliniken AG has a market capitalization of 271.59M EUR, with a price-to-earnings (P/E) ratio of 15.78, indicating moderate valuation relative to its earnings. The price-to-book (P/B) ratio of 2.48 suggests that the market values the companys assets at a premium compared to its book value. The return on equity (RoE) of 18.45% highlights strong profitability. However, the forward P/E ratio is currently 0.00, which may reflect limited visibility into future earnings or the companys growth prospects. The companys operations are supported by a diverse revenue stream from both its Beauty and Trade segments, with a focus on high-margin aesthetic medicine services.

3-Month Forecast - Technical Outlook: The stock is currently trading below its 20-day and 50-day simple moving averages (SMA), with a last price of 14.30 EUR, slightly below the SMA 20 (14.50) and SMA 50 (15.19). The average true range (ATR) of 0.58 suggests moderate volatility. This indicates potential short-term downward pressure, with resistance at the SMA 20 and SMA 50 levels. - Fundamental Outlook: The companys strong return on equity (RoE) of 18.45% and established market position in aesthetic medicine suggest resilience. However, the low price-to-sales (P/S) ratio of 0.81 indicates undervaluation relative to its revenue. Over the next 3 months, the stock is likely to remain range-bound between 13.70 and 15.50 EUR, with potential stabilization if the company demonstrates earnings growth or improved forward guidance.